Foghorn Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Foghorn Therapeutics Inc. on June 24, 2026. The filing details the results of four proposals submitted to security holders, including director elections, auditor ratification, and executive compensation advisory votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following proposals were voted upon by 51,708,896 shares present or represented by proxy out of 58,713,922 shares entitled to vote:
- Director Elections: Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall were elected as Class III directors for three-year terms. Simba Gill received the highest support (45,956,872 votes for), while Douglas Cole received significant opposition (10,987,092 votes against).
- Auditor Ratification: Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 51,661,238 votes in favor.
- Executive Compensation (Say-on-Pay): Stockholders approved the compensation of named executive officers on an advisory basis with 45,637,005 votes in favor.
- Compensation Vote Frequency: Stockholders approved holding future advisory votes on executive compensation annually (one year), with 45,574,407 votes in favor.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves strictly as a record of the Annual Meeting vote tallies.
Investor Verification Checklist
- Verify the specific reasons for the high number of "Against" votes (10,987,092) cast for director nominee Douglas Cole, M.D.
- Review the Proxy Statement filed on April 30, 2026, for detailed biographies of the elected directors and the rationale behind the executive compensation package.
- Confirm the company's financial status and cash runway in the most recent 10-K or 10-Q, as this 8-K contains no financial data.